Some links on this page are affiliate links: if you buy through them we may earn a commission, at no extra cost to you.
The FDA regulates the in vitro diagnostic (IVD) product, while CLIA regulates how a laboratory performs testing. That distinction explains why a laboratory-developed test (LDT) can be performed in a CLIA-certified laboratory without being “FDA approved,” and why a commercial blood-testing device usually needs an FDA classification and premarket pathway. The legal position changed recently: a federal court vacated FDA’s May 2024 LDT rule on March 31, 2025, and FDA issued a September 19, 2025 rule restoring the regulation’s pre-2024 wording. The 2024 phaseout calendar is therefore historical, not a current blanket deadline.
This guide separates FDA device oversight from CLIA laboratory oversight, explains the rules for blood tests and glucose meters, and shows what manufacturers, laboratories, clinicians and patients should verify before relying on a result.
What does the FDA regulate, and what does CLIA regulate?
FDA and CLIA oversee different objects. FDA regulates an IVD as a medical device (and, in some cases, also as a biological product). CLIA regulates the laboratory operation that performs testing on human specimens. A laboratory can meet CLIA requirements and still be using a device that has not received FDA clearance or approval; conversely, an FDA-authorized device must still be used by a laboratory that meets applicable CLIA requirements.
Recommended Free Tools
FDA’s IVD overview describes IVDs as reagents, instruments and systems intended to collect, prepare or examine human specimens to diagnose disease or determine a person’s health status. IVDs are devices under section 201(h)(1) of the Federal Food, Drug, and Cosmetic Act and may also be biological products under section 351 of the Public Health Service Act. FDA applies premarket and postmarket controls; CLIA covers laboratory certification, personnel qualifications, proficiency testing, patient-test management, quality assurance, quality control and inspections.
Popular on Amazon
- 【90 Degree Full Function USB C Adapter】Supports the latest USB4 standard for up to 40Gbps of bandwidth, 8K video support, and up to 240W Fast charging; Support USB PD 3.1 Extended Power Range (EPR) including 140W, 180W and 240W. Your productivity is easily doubled. *Warm Tip: For the best fit, please make sure the USB-C port is fully exposed; thick or bulky cases may affect compatibility.
- 【Reliable Quality】Made from high-quality, scratch-resistant aluminum alloy, delicate metal frame. get excellent wear resistance and heat dissipation. Non-Slip Design for easier insertion and removal.
- 【Small and portable】Ultra thin size, ultra compact design, a petite physique that matches the minimalist design of your modern laptops. Coming with a slim figure that won't block the port next to the one it's plugged into.
- 【Compatibility】Widely work with most usb c, thunderbolt 4/3 devices. Compatibilit for ROG Ally, Steam Deck, Switch, MacBook Pro, Quest 3 VR headset, Surface Book 2, iPhone 18/17/16/15, Samsung Galaxy S23/S22/S21, Note 20/10, Google Pixel, ChromeBook, etc.
- 【Excellence Customer Support】If you experience any issues or cable failure, simply reach out to our dedicated customer service team. We provide a prompt response within 18 hours, providing you with the necessary technical support to resolve any concerns.
For a moderate- or high-complexity laboratory, CLIA compliance is not optional simply because a test is called an LDT. CLIA certification addresses the competence and processes of the laboratory; it does not confer FDA clearance, approval or authorization on the test system.
What is a laboratory-developed test under FDA’s definition?
FDA’s definition is narrower than the everyday use of “in-house test.” An LDT is an IVD intended for clinical use and designed, manufactured and used within a single laboratory that is certified under CLIA and meets CLIA requirements for high-complexity testing. FDA states that definition in its Laboratory Developed Tests materials and repeated it in a May 14, 2024 webinar transcript.
The “single laboratory” condition matters. A kit manufactured for shipment to many unrelated laboratories is generally a commercial IVD, not an LDT merely because a laboratory validates it. Likewise, a test developed in one facility and routinely performed at several affiliated sites may require a careful regulatory analysis of where it is designed, made and used. The intended use, manufacturing activities, distribution and the laboratory’s CLIA status all matter.
Calling a test an LDT does not make it FDA approved. FDA authorization depends on the device’s classification and the applicable pathway. A laboratory may legally perform a test under CLIA while the underlying device has no FDA marketing authorization, subject to the FDA’s current enforcement posture and other applicable law.
What is the current legal status of FDA’s LDT policy?
The current position must be stated with dates. On May 6, 2024, FDA published a final rule that added language to 21 CFR 809.3(a) and announced a staged phaseout of general enforcement discretion for most LDT-related device requirements. On March 31, 2025, a federal district court vacated that rule. FDA then issued a final rule on September 19, 2025, reverting the regulation text to the wording that existed before the 2024 rule. FDA’s current LDT page reflects that reversal.
As a result, the 2024 phaseout dates should be treated as historical policy details unless a newer statute, court decision or FDA action changes the legal framework. They are not current deadlines that can safely be presented as mandatory today. FDA can still enforce the FD&C Act and other authorities in particular circumstances, and laboratories and manufacturers remain responsible for applicable CLIA, device, reporting and safety obligations.
Also popular on Amazon
- 5-in-1 Connectivity: Equipped with a 4K HDMI port, a 5 Gbps USB-C data port, two 5 Gbps USB-A ports, and a USB C 100W PD-IN port. Note: The USB C 100W PD-IN port supports only charging and does not support data transfer devices such as headphones or speakers.
- Powerful Pass-Through Charging: Supports up to 85W pass-through charging so you can power up your laptop while you use the hub. Note: Pass-through charging requires a charger (not included). Note: To achieve full power for iPad, we recommend using a 45W wall charger.
- Transfer Files in Seconds: Move files to and from your laptop at speeds of up to 5 Gbps via the USB-C and USB-A data ports. Note: The USB C 5Gbps Data port does not support video output.
- HD Display: Connect to the HDMI port to stream or mirror content to an external monitor in resolutions of up to 4K@30Hz. Note: The USB-C ports do not support video output.
- What You Get: Anker 332 USB-C Hub (5-in-1), welcome guide, our worry-free 18-month warranty, and friendly customer service.
The 2024 rule’s stated policy goal was to bring more consistent oversight to tests that can drive important medical decisions. FDA Commissioner Robert M. Califf said the rule aimed to help ensure that decisions were based on results patients and clinicians could trust. That policy rationale remains useful context, but it does not restore a vacated rule.
How does FDA regulate an IVD product?
FDA’s device framework follows the product’s risk and intended use. The main steps are:
- Define intended use. The analyte, specimen type, target population, clinical purpose and claims on labeling determine the regulatory question. A screening claim, a diagnostic claim and a monitoring claim can lead to different requirements.
- Classify the device. FDA places devices in Class I, II or III. Classification reflects risk and the controls needed to provide reasonable assurance of safety and effectiveness.
- Select a premarket pathway. Depending on classification and whether a suitable predicate exists, the sponsor may use 510(k) premarket notification, the De Novo classification process or a premarket approval (PMA) application. Some lower-risk devices may be exempt from premarket submission but remain subject to other controls.
- Meet quality requirements. Design and manufacturing controls, validation, document control, purchasing controls, corrective and preventive action, complaint handling and other quality-system duties apply according to the device’s requirements and the manufacturer’s activities.
- Provide compliant labeling. IVD labeling is governed in part by 21 CFR part 809. Instructions must state intended use, specimen requirements, limitations, warnings, performance information and other information needed for safe interpretation.
- Register and list when required. Establishments generally register with FDA and list devices, subject to statutory and regulatory exceptions.
- Maintain postmarket controls. Medical-device reporting, complaint files, corrections and removals, recalls and FDA inspections can apply after marketing. Investigational-use requirements apply when a device is used to generate data for an investigational purpose rather than ordinary clinical diagnosis.
FDA’s overview of IVD regulation explains how these controls interact. The exact obligations depend on the device, its class, the establishment’s role and whether the product is marketed, investigational or used only within a qualifying laboratory.
How is an LDT different from an FDA-cleared or FDA-approved IVD?
The practical difference is not simply “FDA versus no FDA.” It is who makes and performs the test, where it is used, what evidence supports the claims and which controls apply.
| Question | LDT | FDA-cleared or FDA-approved IVD |
|---|---|---|
| Who makes and performs it? | Designed, manufactured and used within one CLIA-certified, high-complexity laboratory. | Manufactured or distributed as a medical device for use according to FDA-authorized labeling. |
| Primary operational oversight | Laboratory operation is overseen under CLIA; FDA device obligations depend on the current law and enforcement posture. | Laboratory still must meet CLIA requirements, while the product is subject to FDA device controls. |
| Premarket status | Not automatically cleared or approved. The laboratory’s validation does not equal FDA authorization. | Has an applicable FDA authorization, such as 510(k) clearance, De Novo classification or PMA approval, unless an exemption applies. |
| Evidence and claims | Laboratory establishes analytical performance and clinical validity appropriate to its intended use under applicable requirements. | FDA reviews the evidence required for the chosen pathway and the specific labeled intended use. |
| Distribution | Use is confined to the qualifying laboratory under the LDT definition. | May be distributed to other authorized users within the scope of its labeling and authorization. |
| Postmarket duties | CLIA quality systems and any applicable FDA reporting or enforcement requirements. | Device reporting, complaints, corrections/removals, quality-system and inspection obligations, plus CLIA controls at the testing laboratory. |
Some products do not fit neatly into a label. An assay may begin as an in-house method and later be packaged, transferred or marketed to other laboratories, changing the regulatory analysis. The safest approach is to evaluate the actual design, manufacturing, use and claims rather than rely on the product name.
Outdated Drivers Are Slowing You Down
One free scan finds every outdated or missing driver and matches the right update for your exact hardware.Free scan · exact hardware matchWindows Errors? Fix Them Before They Spread
Repair common Windows errors and clear accumulated junk for a smoother, more stable PC - no reinstall needed.Free scan · no reinstallWhat were the 2024 LDT phaseout dates?
FDA’s 2024 FAQ described a staged policy for most LDTs. Because the rule was vacated and the text reverted in 2025, these dates are historical and should not be presented as current universal deadlines.
Also popular on Amazon
- Sleek 7-in-1 USB-C Hub: Features an HDMI port, two USB-A 3.0 ports, and a USB-C data port, each providing 5Gbps transfer speeds. It also includes a USB-C PD input port for charging up to 100W and dual SD and TF card slots, all in a compact design.
- Flawless 4K@60Hz Video with HDMI: Delivers exceptional clarity and smoothness with its 4K@60Hz HDMI port, making it ideal for high-definition presentations and entertainment. (Note: Only the HDMI port supports video projection; the USB-C port is for data transfer only.)
- Double Up on Efficiency: The two USB-A 3.0 ports and a USB-C port support a fast 5Gbps data rate, significantly boosting your transfer speeds and improving productivity.
- Fast and Reliable 85W Charging: Offers high-capacity, speedy charging for laptops up to 85W, so you spend less time tethered to an outlet and more time being productive.
- What You Get: Anker USB-C Hub (7-in-1), welcome guide, 18-month warranty, and our friendly customer service.
| Historical date | 2024 policy expectation |
|---|---|
| May 6, 2025 | Medical-device reporting and correction/removal reporting. |
| May 6, 2026 | Establishment registration and device listing, labeling and investigational-use requirements. |
| May 6, 2027 | Quality-system requirements. |
| November 6, 2027 | Premarket review for high-risk tests. |
| May 6, 2028 | Premarket review, when required, for moderate- and low-risk tests. |
The same FAQ described targeted enforcement discretion for categories including certain previously marketed tests, some manual tests resembling those in use before 1976, tests made within integrated health systems for unmet needs and tests approved by New York State’s Clinical Laboratory Evaluation Program (NYS CLEP). Those policies must be checked against current FDA statements and any later legal authority before being relied upon.
FDA’s 2024 regulatory-impact analysis estimated annualized benefits and costs for that now-vacated rule. At a 7% discount rate, estimated benefits ranged from $0.99 billion to $11.1 billion, with a primary estimate of $3.51 billion; estimated costs ranged from $566 million to $3.56 billion, with a primary estimate of $1.29 billion. These are historical model estimates, not measurements of the current regime.
How does FDA regulate blood-testing devices?
Blood is a human specimen, so tests that examine blood are IVDs. The FDA center involved depends on the test’s purpose. The Center for Biologics Evaluation and Research (CBER) regulates all IVD tests used for blood-donor screening, including tests for HIV, HTLV-1/2 and hepatitis B and C. CBER also regulates blood-collection and blood-processing devices. The Center for Devices and Radiological Health (CDRH) regulates other IVDs, subject to the exceptions FDA describes. FDA summarizes the division in its CBER medical-device guidance.
Quick wins for a faster PC:
Scan for outdated or missing drivers - takes under a minuteDriver Scan →Repair Windows errors before they cause bigger problemsFix Now →Donor-screening tests have a high-consequence use: a false-negative result can expose recipients to infection, while a false-positive can discard a donation and defer a donor. Their evidence, labeling, manufacturing and postmarket controls therefore must be evaluated in the context of blood safety, not merely as consumer diagnostic products.
What rules apply to a home blood-glucose meter?
A typical over-the-counter blood-glucose monitoring system contains a handheld meter and single-use test strips. The meter reads a small whole-blood sample and reports a quantitative glucose result. FDA lists glucose test systems under 21 CFR 862.1345 as Class II devices with 510(k) as the submission type.
FDA’s blood-glucose monitoring guidance tells users to use new strips authorized for sale in the United States, follow the meter’s instructions and avoid sharing over-the-counter systems. Sharing can transmit bloodborne pathogens even when the lancet is changed, because the meter or lancing components may become contaminated. Meter-and-strip compatibility is specific: a strip from a different system may produce an unreliable or impossible result.
Also popular on Amazon
- Portable and powerful USB-C HUB: BENFEI USB Type-C HUB, with super-soft and knot-free silicone woven design cable, meets most mobile office needs. Compact, lightweight, stylish, and powerful portable USB C Hub equipped with 1 x HDMI port, 1 x 100W charging, and 3 x USB ports. 18-month warranty, 24-hour response, to ensure you feel at ease when using our product.
- Design centered on comfort and reliability: Thanks to BENFEI's end-to-end in-house cable production capability, in-house PCBA and assembly capability, using the industry's most advanced silicone woven design and process, 20cm cable in length, no knots, super-soft, the HUB is easy to use in all scenarios: laptop, tablet, stand etc. Super-soft, 25000+ life cycles, to meet your daily carrying and office needs.
- 100W Charging: Support up to 90W USB C pass-through charging via Type-C port to keep your laptop powered. 10W is reserved for other interface operations. No data and video function on the Type-C port.
- 4K HDMI Display: The HDMI port supports media display at resolutions up to 4K 30Hz, keeping every incredible moment detailed and ultra vivid. Please note that the C port of the Host device needs to support video output.
- Transfer Files in Seconds: Transfer files and from your laptop at speeds up to 10 Gbps with USB A 3.2 port. Extra 2 USB A 2.0 ports are perfectly for your keyboards and mouse.
Authorization is tied to the exact device configuration and intended use. Before purchasing or relying on a meter, verify the current U.S. authorization status and confirm that the strips, control solution, software and meter model match the labeling. A laboratory or clinician should also consider specimen handling, calibration, interfering substances and whether a result is appropriate for diagnosis, treatment decisions or only routine monitoring.
Do these 3 things before closing this tab:
1Repair Windows errors before they cause bigger problems2Fix the driver behind crashes, sound loss and screen glitches3Clear out junk files and repair common Windows errorsWhat should a laboratory or device developer do now?
The legal reversal does not eliminate the need for disciplined compliance. Use this practical sequence:
- Map the test. Document specimen type, analyte, intended use, users, locations, manufacturing steps and whether the method is distributed outside one laboratory.
- Confirm CLIA status. Identify the laboratory’s certificate type and complexity category. High-complexity status is part of FDA’s LDT definition; CLIA records should match the actual testing site and personnel.
- Check FDA classification. Search FDA’s device databases and classification regulations for a product code, predicate or special control. If the test is a blood-donor screen, determine whether CBER rather than CDRH is the relevant center.
- Choose the regulatory pathway. Analyze whether a 510(k), De Novo request, PMA, exemption or no premarket submission is appropriate. Do not infer the pathway from another assay with a superficially similar name.
- Build evidence around the claim. Validate analytical accuracy, precision, sensitivity, specificity, reportable range, reference intervals and clinically relevant performance as appropriate to the intended use. Keep the evidence and labeling aligned.
- Control changes. Record changes to instruments, reagents, software, suppliers, specimen types and reference materials. Reassess validation and regulatory obligations before implementation.
- Prepare postmarket processes. Maintain complaint intake, adverse-event assessment, corrections and removals, trend review and required reporting. A laboratory should also maintain proficiency testing, quality control and patient-result review under CLIA.
- Communicate limitations. Clinicians and patients need clear instructions about specimen collection, interfering conditions, repeat testing, critical values and when a laboratory or physician must confirm a result.
Regulatory counsel or the appropriate FDA program may be necessary for borderline cases, especially when a test is moving from one laboratory to multiple sites, making a diagnostic claim or supporting blood-donor screening.
Independent reader supportYour contribution helps us test, update, and keep practical guides available for everyone.What mistakes cause the most confusion?
- “CLIA certified” means FDA approved. It does not. CLIA certifies laboratory operations; FDA authorization applies to a device and its intended use.
- Every in-house assay is an LDT. The LDT definition requires design, manufacture and use within one qualifying laboratory. Distribution and centralized testing can change the analysis.
- The 2024 calendar is still in force. It was tied to a rule vacated on March 31, 2025. State the date and legal status whenever discussing those milestones.
- A cleared meter works with any strip. Meter-and-strip systems are matched products. Use only the strip specified by the manufacturer and FDA-authorized for that system.
- A single accuracy number proves clinical usefulness. Analytical performance does not by itself establish that a test is clinically valid for every population, disease stage or decision.
- One FDA center regulates every blood test. CBER handles donor-screening IVDs and blood-collection/processing devices; CDRH handles other IVDs subject to FDA’s stated exceptions.
What should patients ask about an LDT or blood test?
Ask who performs the test, whether the laboratory is CLIA certified for the required complexity, what the test is intended to detect, whether it has FDA authorization for that use and what follow-up is recommended for an unexpected result. For a home glucose system, check the exact meter-and-strip model, expiration dates, storage conditions and the instructions for confirming a result that does not match symptoms.
An LDT can be clinically useful without being FDA approved, but its status should be described accurately. Patients should not treat “laboratory developed,” “CLIA certified” or “FDA registered” as interchangeable with “FDA cleared” or “FDA approved.”
The Tool Desk
Outbyte Driver Updater FREEFix the driver behind crashes, sound loss and screen glitchesFind Drivers →Outbyte PC Repair FREEClear out junk files and repair common Windows errorsFree Scan →Why does the distinction matter for trust in results?
FDA and CLIA address different failure points. FDA review and device controls focus on the product’s design, manufacturing, labeling and evidence for its intended use. CLIA focuses on whether the laboratory has qualified staff, validated procedures, reliable quality control, proficiency testing and safeguards for reporting patient results. A trustworthy result depends on both the test system and the way the laboratory uses it.
Also popular on Amazon
- 【Read before You Buy】 Note: This adapter is USB 2.0 version and cannot transmit HDM, VGA, or other video signals. Nevertheless, they are fully capable of charging devices,duplicating files, and can be seamlessly integrated with USB-C earphones, wireless network adapters, and SD card adapters.
- 【Easy to Use and Safe】Thanks to modern manufacturing techniques, we've made these adapters sufficiently compact so that they can remain inserted in your device without noticeable protrusion or inconvenience. This means you don't have to constantly plug and unplug them, reducing the likelihood of wear and misalignment, and making them more convenient to carry around.
- 【Reliable Quality】Engineered for enhanced durability, durable aluminum alloy shell material,get excellent wear resistance and heat dissipation,the male USB C and female USB connectors & the male USB and female USB C connectors are designed to be plugged and unplugged up to 20000 times. Provides data transfer, device charging, memory space expansion, and additional computer peripherals.
- 【Think more for you】Do you need to connect a USB-C-enabled device to an odd device that only has USB-A ports? Then these USB-A male to USB-C female adapters are made for you.Simply insert the adapter into the USB-A port on the device, and you can instantly connect your USB-C device to the device that originally didn't have the correct connection port.
- 【Trusted xiwxi Quality and Service】As a responsible brand seller, you will receive xiwxi's 12-month Quality assurance and lifetime friendly customer service, you're not just buying a product,you're investing in peace of mind with all-round quality and exceptional customer service.
The 2025 legal reversal means readers should be cautious with articles that present the 2024 phaseout as settled current law. The durable lesson is simpler: identify the product, identify the laboratory, identify the intended use and then verify the FDA and CLIA requirements that apply to each.
Frequently Asked Questions
Can a laboratory-developed test be used if it is not FDA approved?
Potentially, yes. An LDT may be performed within a qualifying CLIA-certified high-complexity laboratory, but CLIA certification is not FDA authorization and the laboratory must follow applicable current FDA, CLIA and other legal requirements. The answer depends on the test’s design, manufacture, use, claims and any FDA enforcement policy that applies.
Does FDA inspect laboratories that perform LDTs?
FDA and CLIA have different inspection roles. CLIA inspections examine laboratory operations and quality systems, while FDA can inspect establishments and investigate device-related compliance under the FD&C Act. A laboratory may therefore face obligations to both programs.
Free tools Windows power users keep installed
One-click scans. No signup required.
Are blood-donor screening tests treated like ordinary home blood tests?
No. FDA’s CBER regulates IVDs used to screen blood donors, including HIV, HTLV-1/2 and hepatitis B and C tests, because the results protect transfusion recipients. Home glucose meters and other non-donor IVDs generally fall under CDRH’s device framework, subject to FDA’s listed exceptions.
How can I check whether a glucose meter is authorized in the United States?
Start with the exact meter model and strip name, then consult FDA’s device information and the manufacturer’s current labeling. Confirm that the strips are authorized for that system, have not expired and are used exactly as instructed; authorization of one meter does not cover unrelated strips or configurations.
Say something about this film